Please login to the form below

Not currently logged in
Email:
Password:

Kala names Howard Rosen as chairman

He is former CEO of Pearl Therapeutics and VP at Gilead
Howard Rosen, Kala

Kala Pharmaceuticals has appointed life sciences industry veteran Howard Rosen as chairman of the board of directors.

Rosen has held several senior roles at major biotechs, including his current positions on the board of directors at AcelRX, Aldea, Entrega and PaxVax, where he is also chairman.

His non-board experience includes serving as president and CEO of Pearl Therapeutics, which was acquired by AstraZeneca last year in a deal worth up to $1.15bn, as well as a period as VP, commercial strategy at Gilead Sciences and president of Johnson & Johnson subsidiary ALZA Corporation.

Kala's president and CEO Guillaume Pfefer commented on this rich experience when welcoming Rosen.

“Howard's extensive track record of building and guiding successful companies will be extremely helpful to Kala at this critical juncture as we advance a rich pipeline of ophthalmology product candidates into clinical development,” said Pfefer, who joined the eyecare specialist from Sanofi in 2012.

8th January 2014

From: Research

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Videum Health

Videum Health is a premium video platform that offers brands innovative engagement strategies to reach targeted healthcare audiences on a...

Latest intelligence

How ‘Greenwashing’ accusations could delay the very changes its supporters demand
Are shouts of companies ‘greenwashing’ to provide a façade of environmental and ethical respectability causing more harm than good? Or should we call out practices that we believe are papering...
What does the future hold for clinical trial recruitment?
The past couple of years have raised several aspects of healthcare in the public’s consciousness – and one of the leading ones has been the role of clinical trials in...
When is an agency not an agency?
The PR Week UK Top 150 Consultancies prompts anticipation and curiosity. But can a virtual collective of freelancers fairly be compared and ranked against conventional agencies?...